Understand Alzheimer's Treatment Options: A Clinical Overview of Current Care

Understanding Alzheimer’s treatment options requires separating medicines that temporarily improve or stabilize symptoms from therapies intended to modestly slow disease progression. Current care may include cognitive medicines, behavioral support, anti-amyloid antibodies for eligible people with early Alzheimer’s, and practical interventions involving sleep, activity, safety, and caregivers.1

What current treatment can and cannot do

There is still no definitive therapy that stops or reverses Alzheimer’s disease. Existing care aims to preserve cognition and daily function for as long as possible, reduce distressing symptoms, address medical contributors, and support the person and caregivers. Classical symptomatic medicines can alleviate or stabilize symptoms for a period, but they do not change the underlying disease course.1

Alzheimer’s treatment decisions depend on disease stage, confirmed diagnosis, other medical conditions, side-effect risk, personal goals, and available monitoring. The treatment landscape has expanded because lecanemab and donanemab received traditional U.S. Food and Drug Administration approval for early Alzheimer’s, but these therapies do not represent a cure and are not designed for every stage or every patient.2

Medicines for cognitive symptoms

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors used to treat cognitive symptoms, particularly in mild to moderate Alzheimer’s disease. Donepezil may also be used in severe disease. These medicines may produce modest improvement or stabilization in memory, thinking, or global function, although tolerability and limited durability can restrict their usefulness.1

Memantine is approved for moderate to severe Alzheimer’s disease and may be prescribed alone or alongside a cholinesterase inhibitor. The choice between medicines, or the decision to combine them, is individualized according to disease severity, response, side effects, and other health conditions. These drugs support symptoms rather than removing amyloid plaques or halting neurodegeneration.4

Anti-amyloid disease-modifying therapies

Lecanemab, marketed as Leqembi, is approved for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmed amyloid pathology. Donanemab, marketed as Kisunla, is also approved for adults in these early symptomatic stages with confirmed amyloid pathology. Both target amyloid and can modestly slow cognitive and functional decline rather than restore lost abilities.2

Eligibility requires more than a memory complaint. Clinicians generally establish the disease stage, confirm amyloid pathology through an appropriate biomarker assessment, review medical history and medicines, and consider whether repeated imaging is practical. Donanemab treatment duration may depend on plaque reduction and clinical assessment, while lecanemab is administered on an ongoing treatment schedule determined by its prescribing framework and specialist care.6

Safety, monitoring, and practical burdens

A major risk of anti-amyloid antibody treatment is amyloid-related imaging abnormalities, known as ARIA. ARIA can involve brain swelling or bleeding and may be detected on MRI before symptoms appear, although some people experience headache, confusion, dizziness, or other neurological symptoms. Risk assessment and scheduled MRI monitoring are central parts of treatment, not optional additions.2

Anti-amyloid treatment also involves repeated clinical visits, intravenous administration, imaging, biomarker confirmation, and coordination among specialists. Blood-thinning medicines and other medical factors may affect the benefit versus risk assessment. Medicare coverage exists under specified coverage-with-evidence-development requirements, including appropriate clinical settings and registry or study participation, so coverage and access conditions should be verified with qualified professionals.5

Non-drug care and caregiver support

Non-drug interventions are a core part of Alzheimer’s treatment at every stage. Regular physical activity, cognitive and social engagement, attention to sleep, treatment of hearing or vision problems, medication review, and structured daily routines can support function and quality of life. These measures do not cure Alzheimer’s, but they may address modifiable contributors to confusion, inactivity, falls, and distress.2

Caregiver support includes education, planning for changing abilities, supervision of medicines and finances, home safety assessment, and preparation for increased help with daily activities. Behavioral changes should first prompt evaluation for pain, infection, medication effects, sleep disruption, environmental stress, or unmet needs. A coordinated plan is often more sustainable than relying on medication alone.4

Behavioral and psychological symptoms

Agitation, anxiety, depression, sleep disruption, hallucinations, and delusions may occur during Alzheimer’s disease. Initial management generally emphasizes calm communication, predictable routines, meaningful activity, reduced environmental triggers, and assessment for physical causes. Treatment should reflect the symptom’s severity, duration, safety impact, and effect on the person’s daily life and caregivers.3

Antipsychotic medicines may be considered in selected situations involving severe distress, psychosis, or danger when non-drug approaches are insufficient. They carry important risks for older adults with dementia and therefore require careful prescribing, monitoring, and reassessment. A medication review should distinguish Alzheimer’s symptoms from depression, delirium, medication reactions, or other neurological and medical conditions.4

Clinical trials and emerging approaches

Clinical trials remain an important part of the treatment landscape because researchers are studying therapies aimed at tau pathology, neuroinflammation, metabolic dysfunction, prevention, vaccines, combination approaches, and improved diagnosis or monitoring. The existence of an investigational therapy does not establish that it is effective or safe, and eligibility can depend on disease stage, biomarkers, health status, and study design.1

ClinicalTrials.gov provides a registry of ongoing and completed Alzheimer’s intervention studies, while NIH-supported research is evaluating treatments at different disease stages and investigating blood biomarkers that may help identify participants. Research participation requires review of the protocol, possible risks, travel and visit requirements, placebo considerations, and the distinction between research procedures and established clinical care.7

How treatment choices are evaluated

A practical treatment discussion begins with confirming the diagnosis and documenting the person’s baseline cognition, function, symptoms, medicines, vascular risks, and care environment. For symptomatic medicines, the central questions are whether the expected benefit is meaningful and whether adverse effects are acceptable. For anti-amyloid therapy, the evaluation additionally includes confirmed amyloid pathology, early disease stage, MRI findings, bleeding risk, monitoring capacity, and treatment goals.6

No single option fits every person with Alzheimer’s disease. A balanced plan may combine a symptom medicine, non-drug strategies, caregiver support, management of sleep or psychiatric symptoms, and advance planning. Anti-amyloid antibodies add a disease-modifying option for a narrower eligible population, but their modest clinical effect, ARIA risk, monitoring demands, and coverage conditions require individualized specialist assessment rather than automatic treatment.2

Sources

1. Healio, “Treatment Options | Alzheimer’s Disease,” https://www.healio.com/clinical-guidance/alzheimers-disease/treatment-options-treatment-options
2. National Institute on Aging, “Preventing and Treating Alzheimer’s Disease and Related Dementias,” https://www.nia.nih.gov/about/2024-nih-dementia-research-progress-report/preventing-treating-alzheimers-disease-related-dementias
3. U.S. Food and Drug Administration, Alzheimer’s disease treatment and approval information, https://www.fda.gov/consumers/consumer-updates/alzheimers-disease-what-you-need-know
4. Mayo Clinic, “Alzheimer’s treatments,” https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780
5. Centers for Medicare & Medicaid Services, National Coverage Determination 200.3, https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=375
6. Alzheimer’s Association, “Treatments,” https://www.alz.org/alzheimers-dementia/treatments
7. ClinicalTrials.gov, Alzheimer Disease studies, https://clinicaltrials.gov/search?cond=Alzheimer%20Disease